Clofazimine: An old drug for never-ending diseases: Future Microbiology

N. Riccardi, A. Giacomelli, D. Canetti, A. Comelli, E. Intini, G. Gaiera, M.M. Diaw, Z. Udwadia, G. Besozzi, L. Codecasa, A.D. Biagio

Research output: Contribution to journalArticlepeer-review


Clofazimine (CFZ), an old hydrophobic riminophenazine, has a wide range of antimycobacterial activity ranging from leprosy to nontuberculous mycobacterial diseases. CFZ has several advantages such as a favorable pharmacokinetic profile, dose-dependent side effects as well as low price. In this narrative review, we have assessed the clinical development of CFZ, starting from the potential in vitro mechanism of actions, to the spectrum of side effects and potential drug-drug interactions, highlighting its current place in therapy and future possible use in leprosy, nontuberculous mycobacterial diseases and drug-resistant tuberculosis. © 2020
Original languageEnglish
Pages (from-to)557-566
Number of pages10
JournalFuture Microbiol.
Issue number7
Publication statusPublished - 2020


  • clofazimine
  • leprosy
  • MDR-TB
  • NTM
  • XDR-TB
  • adverse drug reaction
  • antibacterial activity
  • antibiotic therapy
  • chemical structure
  • drug mechanism
  • drug resistant tuberculosis
  • drug safety
  • drug tolerability
  • human
  • mycobacteriosis
  • nonhuman
  • pharmacokinetic parameters
  • priority journal
  • Review
  • systematic review


Dive into the research topics of 'Clofazimine: An old drug for never-ending diseases: Future Microbiology'. Together they form a unique fingerprint.

Cite this